Strs Ohio Grows Stock Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Strs Ohio increased its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 256.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 193,000 shares of the biotechnology company’s stock after buying an additional 138,900 shares during the quarter. Strs Ohio owned about 0.27% of Aclaris Therapeutics worth $202,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Aclaris Therapeutics by 1.0% during the third quarter. Vanguard Group Inc. now owns 3,363,046 shares of the biotechnology company’s stock worth $23,037,000 after buying an additional 33,482 shares during the last quarter. Trexquant Investment LP purchased a new position in shares of Aclaris Therapeutics during the third quarter worth about $876,000. SG Americas Securities LLC grew its holdings in shares of Aclaris Therapeutics by 20.1% during the third quarter. SG Americas Securities LLC now owns 151,704 shares of the biotechnology company’s stock worth $1,039,000 after buying an additional 25,357 shares during the last quarter. Blackstone Inc. boosted its holdings in Aclaris Therapeutics by 9,578.7% in the 3rd quarter. Blackstone Inc. now owns 1,261,425 shares of the biotechnology company’s stock valued at $8,641,000 after purchasing an additional 1,248,392 shares in the last quarter. Finally, Barclays PLC boosted its holdings in Aclaris Therapeutics by 174.2% in the 3rd quarter. Barclays PLC now owns 234,150 shares of the biotechnology company’s stock valued at $1,603,000 after purchasing an additional 148,761 shares in the last quarter. Hedge funds and other institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Price Performance

Shares of NASDAQ:ACRS opened at $1.21 on Wednesday. The business’s 50 day simple moving average is $1.22 and its 200-day simple moving average is $1.68. The firm has a market capitalization of $86.22 million, a price-to-earnings ratio of -0.95 and a beta of 0.22. Aclaris Therapeutics, Inc. has a 12 month low of $0.59 and a 12 month high of $11.12.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.07. Aclaris Therapeutics had a negative return on equity of 64.56% and a negative net margin of 283.15%. The firm had revenue of $17.57 million during the quarter, compared to the consensus estimate of $3.96 million. On average, equities analysts anticipate that Aclaris Therapeutics, Inc. will post -0.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Aclaris Therapeutics in a report on Friday, January 12th. BTIG Research reaffirmed a “neutral” rating on shares of Aclaris Therapeutics in a report on Thursday, January 11th. HC Wainwright lowered Aclaris Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, January 22nd. Finally, StockNews.com lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, April 2nd. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $22.25.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.